Cassifarma SRL
Cassifarma reported total assets of 942,826 € at the end of the 2025 financial year (annual accounts filed with the NBB on 28 Jul 2026).
The score of Cassifarma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +90 % Total assets +2 %
Accounts of the company itself (not consolidated).
The full file covers 7 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Cassifarma's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 66,323 € | ||||
| Equity | 398,795 € | ||||
| Cash | 7,235 € | ||||
| EBITDA | 113,700 € | ||||
| Total assets | 942,826 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 28 Jul 2026
- Year ended 31 Dec 2024filed on 14 Jul 2025
- Year ended 31 Dec 2023filed on 31 Aug 2024
- Year ended 31 Dec 2022filed on 21 Aug 2023
- Year ended 31 Dec 2021filed on 09 Sep 2022
Cassifarma's financial analysis
- Solvency42.3%sector median: 44.0%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Cassifarma
Cassifarma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0727.381.719
- VAT number
- BE0727381719
- Peppol
- Registered · 0208:0727381719 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 22 May 2019
- Registered office
- 3000 Leuven
- Latest accounts
- 2025 · filed on 28 Jul 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Cassifarma (SRL) has been based in Leuven since 2019, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 66,323 € and equity of 398,795 €; its revenue is not published. Its solvency stands at 42.3%, below the median of its sector (44.0%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Cassifarma
Companies in the same business, of comparable size and area, outside its group.
- Pharmacie de Neef - Duez Retail sale of pharmaceutical products Mons · balance sheet 181,026 €
- Cosom Retail sale of pharmaceutical products Genappe · balance sheet 931,343 €
- Apotheek van Hecke Retail sale of pharmaceutical products Zele · balance sheet 920,659 €
- Demaphar Retail sale of pharmaceutical products Mons · balance sheet 965,578 €
- Akaption Retail sale of pharmaceutical products Braives · balance sheet 967,311 €
- Geassocieerde Apotheek van Puyvelde Retail sale of pharmaceutical products Antwerp · balance sheet 908,969 €
- Demuphar Retail sale of pharmaceutical products Ghent · balance sheet 978,525 €
- D'Haen Pharma Retail sale of pharmaceutical products Zottegem · balance sheet 987,565 €
Frequently asked questions about Cassifarma
What is the revenue of Cassifarma?
Cassifarma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Cassifarma?
In Belgium, the VAT number is the company number prefixed with BE: BE0727381719 for Cassifarma, if the company is VAT-registered. Its company number (CBE) is 0727.381.719.
Where is the registered office of Cassifarma?
According to the CBE register, the registered office of Cassifarma is in 3000 Leuven.
What is the equity of Cassifarma?
At the close of the 2025 financial year, the equity of Cassifarma amounts to 398,795 €, a solvency of 42.3% of total assets.
Who manages Cassifarma?
The register lists 1 active mandates at Cassifarma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Cassifarma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →